Journal
DRUG RESISTANCE UPDATES
Volume 15, Issue 1-2, Pages 21-38Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2012.01.008
Keywords
Acquired drug resistance; Tumor heterogeneity; Epigenetics; Oncogenic histone modification; Epigenetic therapy
Categories
Funding
- Dutch Cancer Society [KWF 2007-3978]
- Netherlands Organization
Ask authors/readers for more resources
Resistance of cancer cells to chemotherapeutics and emerging targeted drugs is a devastating problem in the treatment of cancer patients. Multiple mechanisms contribute to drug resistance such as increased drug efflux, altered drug metabolism, secondary mutations in drug targets, and activation of downstream or parallel signal transduction pathways. The rapid kinetics, the reversibility of acquired drug resistance and the absence of genetic mutations suggest an epigenetic basis for drug insensitivity. Similar to the cellular variance seen in the human body, epigenetic mechanisms, through reversible histone modifications and DNA methylation patterns, generate a variety of transcriptional states resulting in a dynamic heterogeneous tumor cell population. Consequently, epigenomes favoring survival in the presence of a drug by aberrant transcription of drug transporters, DNA-repair enzymes and pro-apoptotic factors render cytotoxic and targeted drugs ineffective and allow selection of rare drug-resistant tumor cells. Recent advances in charting cancer genomes indeed strongly indicate a role for epigenetic regulators in driving cancer, which may result in the acquisition of additional (epi)genetic modifications leading to drug resistance. These observations have important clinical consequences as they provide an opportunity for epigenetic drugs to change reversible drug-resistance-associated epigenomes to prevent or reverse non-responsiveness to anti-cancer drugs. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available